Advertisement

Topics

Curtana granted FDA Orphan designation for gliomas treatment CT-179

08:31 EDT 16 Aug 2017 | CentreWatch

Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, announced that the FDA has granted orphan drug designation to CT-179, the company’s lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma (GBM) in adults and pediatric high grade glioma in children.  Glioblastoma is the most common and most aggressive of the malignant primary brain tumors […]

The post Curtana granted FDA Orphan designation for gliomas treatment CT-179 appeared first on CenterWatch News Online.

Original Article: Curtana granted FDA Orphan designation for gliomas treatment CT-179

NEXT ARTICLE

More From BioPortfolio on "Curtana granted FDA Orphan designation for gliomas treatment CT-179"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...